Navigation Links
Cancer/Tumor Profiling Market worth $35.03 Billion by 2018
Date:9/26/2013

DALLAS, September 26, 2013 /PRNewswire/ --

The "CANCER/TUMOR PROFILING MARKET [Applications (Personalized Medicine, Diagnostics, Biomarker Discovery, Prognosis, Research), Technologies (NGS, QPCR, IHC, FISH/CISH, Microarray), Segments: Genomics, Proteomics, Metabolomics, Epigenetics)] 2013 - 2018", report analyzes and studies the major market drivers, restraints, and adoption potential in North America, Europe, Asia, and Rest of the World.

Browse market 22 data tables and 50 Figures and spread through 173 slides and in-depth TOC on CANCER/TUMOR PROFILING MARKET 2013 - 2018

http://www.marketsandmarkets.com/Market-Reports/cancer-tumor-profiling-market-1250.html
Early buyers will receive 10% customization on this report.

This report studies the global Cancer/Tumor Profiling Market, with forecast to 2018.

The global healthcare industry is witnessing a paradigm shift, skewed towards point-of-care diagnostics, cost-effective treatment modalities, and personalized medicine, which not only offers efficient early diagnosis, but also treats cancer conditions in order to reduce the healthcare cost and disease burden. Cancer/Tumor Profiling is one such technology with the exact potential to revolutionize cancer diagnostics and therapeutics in the healthcare industry.

This market research report evaluates the global market of Cancer/Tumor Profiling by geography, applications, technologies, and segment types. Further, the applications market is divided into five segments, namely Personalized Medicine, Diagnostics, Biomarker Discovery, Prognosis and Research Applications; the technologies section is divided into five segments, namely Next-Generation Sequencing, Quantitative PCR, Immunohistochemistry, FISH/CISH, and Microarray; and finally, the segment types is partitioned into four parts, namely Genomics, Proteomics, Metabolomics, and Epigenetics. Of the above-mentioned application segments, personalized medicine is the largest revenue segment and NGS is the potential revenue yielding technology.

The global Cancer/Tumor Profiling Market was valued at $13.30 billion in 2012. At the end of 2013, the market is estimated to be $14.99 billion and is poised to reach around $35 billion by 2018, growing at a CAGR of 18.50% from 2013 to 2018.

The diagnostics, biomarker discovery, and prognosis applications offer vast opportunities for key players in this market. The launch of the first and only FDA-cleared IVDMIA breast cancer recurrence assay "MammaPrint", "ColoPrint" - a microarray-based gene expression profile for predicting the recurrence of stage II and III colon cancer patients, "Oncotype Dx" - a test that examines a breast cancer patient's tumor tissue at a molecular level to give information about a patient's individual disease, has acknowledged the potential of Cancer/Tumor Profiling in diagnostics and prognosis. This scenario is expected to further revolutionize the industry towards massive growth in the next 5 to 10 years.

The global market for Cancer/Tumor Profiling is expected to grow, backed by technological advancements, huge funds, and investments. The market is witnessing a trend towards the development of personalized medicine and point-of-care diagnostic tests for cancer. Additionally, the demand for safe and cost-effective drugs for the treatment of cancer (which can be fulfilled by Cancer/Tumor Profiling therapeutics), will fuel the market growth. However, the market will also experience improvements in biomarker discovery and prognosis areas during the forecast period.

North America is the largest hub for Cancer/Tumor Profiling Market, accounting for the largest share, followed by Europe and Asia. North America and Europe are expected to grow at a steady pace. However, the Asia-Pacific market and few countries from the ROW region are expected to witness a boost in demand and are poised to register maximum growth over the next five years, owing to high incidence of cancers, affected population, and the increased purchasing power of patients.

The key players in the Cancer/Tumor Profiling Market are Boreal Genomics Inc. (U.S.), Caris Life Sciences (U.S.), Genomic Health Inc. (U.S.), Illumina Inc. (U.S.), Life Technologies Corporation (U.S.), NeoGenomics Laboratories (U.S.), Oxford Gene Technology Ltd. (U.K.), Precision Therapeutics Inc. (U.S.), bioTheranostics (U.S.), Proteome Sciences PLC (U.K.), Agendia (The Netherlands), Nanostring Technologies (U.S.), Rational Therapeutics (U.S.), Oncopath Laboratories (U.S.), and RiboMed Biotechnologies Inc. (U.S.).

Browse related reports

In Vitro Diagnostic (IVD) Market [Instruments, Reagents & Data Management Systems] [Technique (Immunoassay, Clinical Chemistry, Molecular Diagnostics, Haematology) & Applications (Diabetes, Infectious Diseases, Cancer & Cardiology)] Systems, End Users] - Forecast To 2017

http://www.marketsandmarkets.com/Market-Reports/ivd-in-vitro-diagnostics-market-703.html

Molecular Diagnostics Market - Technologies [PCR, DNA Sequencing, Microarray, Transcription Mediated Amplification, Hybridization], Applications Virology/Infectious Diseases, Cancer/ Oncology, Genetic Testing, Blood Screening, Microbiology] Global Opportunities, Competitor Analysis & Forecasts to 2017

http://www.marketsandmarkets.com/Market-Reports/molecular-diagnostic-market-833.html

About MarketsandMarkets

MarketsandMarkets is a global market research and consulting company based in the U.S. We publish strategically analyzed market research reports and serve as a business intelligence partner to Fortune 500 companies across the world.

MarketsandMarkets also provides multi-client reports, company profiles, databases, and custom research services. MarketsandMarkets covers thirteen industry verticals; including advanced materials, automotives and transportation, banking and financial services, biotechnology, chemicals, consumer goods, telecommunications and IT, energy and power, food and beverages, industrial automation, medical devices, pharmaceuticals, agriculture industry, semiconductor and electronics, aerospace & defense.

We at MarketsandMarkets are inspired to help our clients grow by providing apt business insight with our huge market intelligence repository.

Contact:
Mr. Rohan
North - Dominion Plaza
17304 Preston Road
Suite 800, Dallas, TX 75252
Tel: +1-888-600-6441
Email: sales@marketsandmarkets.com
Visit MarketsandMarkets Blog @http://www.marketsandmarketsblog.com/market-reports/healthcare/biotechnology
Connect with us on LinkedIn @ http://www.linkedin.com/company/marketsandmarkets


'/>"/>
SOURCE MarketsandMarkets
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. GPCR Screening and Profiling Market Trends 2013 in New Research Report at ReportsnReports.com
2. Signal Genetics LLC Announces Update to MyPRS™ Gene Expression Profiling Assay for Multiple Myeloma
3. Caris Life Sciences ASCO Presentation Highlights the Utility of Molecular Profiling for the Management of Rare and Aggressive Cancers
4. Kinase Market Profiling - In House & Outsourced Trends 2015 Forecast in New Research Report at ReportsnReports.com
5. Monitoring Protein Synthesis One Codon at a Time Through Ribosome Profiling, a Webinar Hosted by Xtalks
6. Global Metabolomics (Biomarker Discovery/Metabolite Detection/Metabolite Profiling) - 2013 Market Report
7. Caris Life Sciences Adds Next-Generation Sequencing to Enhance Evidence-Based Tumor Profiling Service for Cancer Patients
8. Caris Sponsors CancerCare Connect Education Workshop on Molecular Profiling in the Treatment of Breast Cancer
9. Caris Life Sciences Enhances Molecular Profiling Service with Addition of ROS1 and MGMT-Methylation Biomarkers
10. Nerve Repair and Regeneration Market - Global Trend and Forecast to 2018
11. MarketPublishers.com Added New Report on Mannitol (CAS 87-78-5) Market to Its Catalogue
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... ... June 23, 2016 , ... STACS DNA Inc., the ... at the Arkansas State Crime Laboratory, has joined STACS DNA as a Field Application ... team,” said Jocelyn Tremblay, President and COO of STACS DNA. “In further expanding our ...
(Date:6/23/2016)... , June 23, 2016 Apellis Pharmaceuticals, ... 1 clinical trials of its complement C3 inhibitor, ... and multiple ascending dose studies designed to assess ... of subcutaneous injection in healthy adult volunteers. ... either as a single dose (ranging from 45 ...
(Date:6/23/2016)... , June 23, 2016 ... Review, 2016;12(1):22-8 http://doi.org/10.17925/OHR.2016.12.01.22 Published ... the peer-reviewed journal from touchONCOLOGY, Andrew D ... cost of cancer care is placing an increasing ... of expensive biologic therapies. With the patents on ...
(Date:6/23/2016)... ... 23, 2016 , ... ClinCapture, the only free validated electronic ... showcase its product’s latest features from June 26 to June 30, 2016 for ... Disrupting Clinical Trials in The Cloud during the conference. DIA (Drug Information ...
Breaking Biology Technology:
(Date:6/3/2016)... 3, 2016 Das ... Nepal hat ein 44 ... geprägter Kennzeichen, einschließlich Personalisierung, Registrierung und IT-Infrastruktur, ... Produktion und Implementierung von Identitätsmanagementlösungen. Zahlreiche renommierte ... Januar teilgenommen, aber Decatur wurde als konformste ...
(Date:6/2/2016)... Perimeter Surveillance & Detection Systems, Biometrics & ... & Other Service  The latest report from ... of the global Border Security market . Visiongain ... billion in 2016. Now: In November 2015 ... and hardware technologies for advanced video surveillance. ...
(Date:5/20/2016)... May 20, 2016  VoiceIt is excited to ... VoicePass. By working together, VoiceIt and ... VoiceIt and VoicePass take slightly different approaches to ... both security and usability. ... this new partnership. "This marketing and ...
Breaking Biology News(10 mins):